October 21, 2014 | The Israeli company Brainsway has reportedly signed a marketing agreement with a French company for its Deep TMS System in France. Brainsway’s Deep TMS (Deep Transcranial Magnetic Stimulation) system is a treatment for depression and other brain disorders that has been approved by the FDA in the United States for the treatment of severe depression. According to the agreement, Brainsway will deal directly with customers recruited by the French company, while paying the latter company a commission for every new customer. In addition, Brainsway announced that BlueCross BlueShield will begin to reimburse patients for Brainsway treatments in the US states of Flordia, Kansas and Missouri, and that Tufts will do so in Massachusetts.
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors

Ashdod Port Investing In Startups As Part Of Innovation Strategy

Facebook comments